AZD5363

Catalog No.S8019

AZD5363 Chemical Structure

Molecular Weight(MW): 428.92

AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Size Price Stock Quantity  
In DMSO USD 235 In stock
USD 147 In stock
USD 470 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

3 Customer Reviews

  • G-H. Analysis of cells treated with AZD5363 (500 nM) for 24 hrs. G.Western analysis of whole cell lysates. H. Cells labeled with Annexin V-FITC for 6h were imaged. Individual points are average for replicates assessed in duplicate. Midlines are the average ± S.D. Student’s T-test.

    Cancer Res, 2016, 76(16):4752-64.. AZD5363 purchased from Selleck.

    Inhibition of PI3K and Akt by LY294002 and AZD5363 was confirmed by analyzing expression and activation status of the ribosomal protein S6 by Western blot analysis of PC-3 clone #14 cells treated with 0.5 or 5 uM AZD5363 (AZD) and 10 uM LY294002 (LY). Tubulin was used as a loading control.

    Cell Commun Signal 2014 12(1), 61. AZD5363 purchased from Selleck.

  • LNCaP, LNCaP95, VCaP and 22Rv1 cells were transfected with control or pooled siRNA for AKT 1–3 isoforms for 36 hours. Cells were then further treated with 5 uM AZD5363 (B) for another 18 hours. Protein lysates were immunoblotted with AR (N-20), AR-V7, Pan-AKT, p-AKT(ser473) and β-Actin antibodies. Results were repeated in more than three independent experiments.

    PLoS One 2014 9(10), e108780. AZD5363 purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.
Features Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
ROCK2 [1]
(Cell-free assay)
3 nM 8 nM 8 nM 56 nM
In vitro

AZD5363 is a potent Akt inhibitor with IC50 of 3 nM, 8 nM and 8 nM for Akt1, Akt2 and Akt3, respectively. [1] AZD5363 inhibits phosphorylation of AKT substrates in cells with a potency of approximately 0.3 to 0.8 μM. AZD5363 inhibits the proliferation of 41 of 182 solid and hematologic tumor cell lines with a potency of < 3 μM. [2] Activating mutations in PIK3CA, loss or inactivation of tumor suppressor PTEN, or HER2 amplification all are significantly predictive of responsiveness to AZD5363. Additionally, correlation is also seen between the RAS mutation status of cell lines and resistance to AZD5363. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 NFzXSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIqzbWozODBibl2= NYXi[YVQPiCm NWHFeok2cW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 NVrTXnBVOjZ|NUGzNlM>
ZR75 MlPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV6xNFAhdk1? NVyzelAyPiCm M{j6[olv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= MmLsNlY{PTF|MkO=
T74D M2HzWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zyflExOCCwTR?= NEXNWHU3KGR? MlrvbY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62 MV:yOlM2OTN{Mx?=
1%MCF7 NUDtVYhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXq0NFAhdk1? MWG2JIQ> M2LKc4lv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= MVeyOlM2OTN{Mx?=
MCF7 LTED MonIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2q4UVIxOCCwTR?= NGjGd5c3KGR? NV;GeY9zcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 NH3Oc5IzPjN3MUOyNy=>
ZR75 LTED Mn;lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYKxNFAhdk1? MlrrOkBl MXfpcoNz\WG|ZXSg[JJ2\yC|ZX7zbZRqfmm2eTDv[kA1NU:KVDDhcoQh\nWudnXzeJJidnR? NYmz[oh6OjZ|NUGzNlM>
T74D LTED NYG2SWs2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTyU4JWOTByIH7N NWK0W5Y4PiCm NVm4Z3ZFcW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 MYGyOlM2OTN{Mx?=
TamR NF;vcXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7lOVk1PDByIH7N Mm\pOkBl NGi3dGJqdmO{ZXHz[YQh\HK3ZzDz[Y5{cXSrdnn0fUBw\iB2LV;IWEBidmRiZoXseoV{fHKjboS= MWiyOlM2OTN{Mx?=
HCC1954 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoW5NE0yNjN3IN88US=> M1HZ[|Uh\A>? M4ToTIVvcGGwY3XzJJRp\SCpcn;3eIghcW6qaXLpeIlwdiCxZjDBXmQ5QTNz NEPQNowzPjB7NUS3OS=>
BT474c M2\5b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mof1NE0yNjN3IN88US=> NHi4VIw2KGR? M1K5UYVvcGGwY3XzJJRp\SCpcn;3eIghcW6qaXLpeIlwdiCxZjDBXmQ5QTNz M3TLNlI3ODl3NEe1
KPL4 M4rqeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LBZ|AuOS5|NTFOwG0> NInE[|Y2KGR? MWflcohidmOnczD0bIUh\3Kxd4ToJIlvcGmkaYTpc44hd2ZiQWrEPFk{OQ>? MkjQNlYxQTV2N{W=
SKBR3 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;Ge4YxNTFwM{Wg{txO NHviOHg2KGR? NIXMbGhmdmijbnPld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[gRXpFQDl|MR?= NULydYFbOjZyOUW0O|U>
MR49C MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MViwMVUh|ryP NF3ONHI1QCCq NYrPVmJxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MmfoNlUyPTFyMUK=
MR49F M3mwd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXGwMVUh|ryP NELtfYM1QCCq NYmydXREcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? M1TlUFI2OTVzMEGy
NCI-H522 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fNWmlEPTB;MUGuN{ApyrF{LkepJO69VQ>? NUfBVYg4OjR7NUe2PFI>
PC-9 NULOVpdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\zdoxKSzVyPUmuN{ApyrFzLkKpJO69VQ>? MlrlNlQ6PTd4OEK=
NCI-H522 M1LvNGZ2dmO2aX;uJGF{e2G7 MmO0NU82NzFyIN88US=> Mo[zOE8zPCCq NGD1[I1qdmO{ZXHz[ZMhSUuWIIDoc5NxcG:{eXzheIlwdg>? M3TJXFI1QTV5Nkiy
PC-9 NVzjb3MxTnWwY4Tpc44hSXO|YYm= MYexM|UwOTBizszN M1XkbVQwOjRiaB?= MUHpcoNz\WG|ZYOgRWtVKHCqb4PwbI9zgWyjdHnvci=> NWfkWoZGOjR7NUe2PFI>
HGC27 NUK0dpNVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTBwNES1JO69VQ>? MnjZNlQxQDh|OEK=
IM95m MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPLTWM2OD1yLkWxJO69VQ>? MlTnNlQxQDh|OEK=
AGS M{jmeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LkeWlEPTB;MD61OVIh|ryP MXuyOFA5QDN6Mh?=
NCI-N87 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD1UnV{UUN3ME2xMlA{PyEQvF2= MoTLNlQxQDh|OEK=
23132/87 M{jXXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTFwNkexJO69VQ>? M4\ZZ|I1ODh6M{iy
MKN1 MmnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\mTlQ3UUN3ME2yMlQzOSEQvF2= NFvW[WgzPDB6OEO4Ni=>
SNU-620 Mlz2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTNwM{i0JO69VQ>? NGHEN4gzPDB6OEO4Ni=>
SNU-638 M2HFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTRwNUKzJO69VQ>? NYTVflJDOjRyOEizPFI>
SNU-1 NH7BN41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTVwMkW4JO69VQ>? NW\4NIRmOjRyOEizPFI>
SNU-601 M4Kycmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfDcFV3UUN3ME21Mlk{QCEQvF2= MluyNlQxQDh|OEK=
SNU-668 M1POcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\xeJNKSzVyPU[uNFA{KM7:TR?= MYeyOFA5QDN6Mh?=
HS746T MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTZwMEi0JO69VQ>? NU\tXZZ4OjRyOEizPFI>
KATO III MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\3VlN6UUN3ME23MlI3PyEQvF2= MYWyOFA5QDN6Mh?=
SNU-484 MmG0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rJUmlEPTB;Nz6zPVIh|ryP NYfUR5lOOjRyOEizPFI>
SNU-16 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;nTWM2OD1zMT6wPVch|ryP Mk\uNlQxQDh|OEK=
OCUM-1 NEH4fpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjPTWM2OD1zND61NVUh|ryP M2nPfFI1ODh6M{iy
NUGC-3 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jkWmlEPTB;MkGuPFc{KM7:TR?= MWSyOFA5QDN6Mh?=
AZ521 M4e4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFvzSW1KSzVyPUK1MlQ1QCEQvF2= M{jZSlI1ODh6M{iy
SNU-216 NYDEbINoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYjuTVhLUUN3ME2zNEDPxE1? MmXPNlQxQDh|OEK=
NUGC-4 NX3YW|l1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEK3NnRKSzVyPUOwJO69VQ>? NGjFemszPDB6OEO4Ni=>
SNU-5 NYLzSm5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXRUZR{UUN3ME2zNEDPxE1? NYnvUZA6OjRyOEizPFI>
GTL-16 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIXzSFNKSzVyPUOwJO69VQ>? NGDmPGEzPDB6OEO4Ni=>
MKN74 MmLxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTNyIN88US=> NV\VRVJCOjRyOEizPFI>
PAMC82 NHrlWFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXRTWM2OD1|MDFOwG0> NHzoeG8zPDB6OEO4Ni=>
LNCaP MkP3SpVv[3Srb36gRZN{[Xl? NXe3c2FiPSEQvF2= MXOwMVI1KGh? MkOzbY5lfWOnczDBT3RUPDd|IHHu[EBCU1SWM{C4JJBpd3OyaH;yfYxifGmxbjDpckBiKHSrbXWg[IVx\W6mZX70JI1idm6nch?= NU\yPYdlOjN7Nk[2NlE>
C4-2  MmP2SpVv[3Srb36gRZN{[Xl? NV7UU5BHPSEQvF2= M4OyR|AuOjRiaB?= M4\pR4lv\HWlZYOgRWtVWzR5MzDhcoQhSUuWVEOwPEBxcG:|cHjvdplt[XSrb36gbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK= MnLuNlM6PjZ4MkG=
LNCaP NHToeoRHfW6ldHnvckBCe3OjeR?= NF7kb5E2KM7:TR?= Mlz3NE0zPCCq M2PIcolvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kB1cGViZHnzeIFtKEGNVD3wZZRpf2G7IHLpc41iemuncoOgbY5kdHWmaX7nJHBTSVN2MDyg[WlHPEVuIETFMWJROSxibWTPVkwh[W6mIGC3NEBUPiCtaX7hd4UhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> NFL3fHMzOzl4Nk[yNS=>
C4-2  Mn\QSpVv[3Srb36gRZN{[Xl? M1vXcVUh|ryP MUGwMVI1KGh? M{OxVIlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kB1cGViZHnzeIFtKEGNVD3wZZRpf2G7IHLpc41iemuncoOgbY5kdHWmaX7nJHBTSVN2MDyg[WlHPEVuIETFMWJROSxibWTPVkwh[W6mIGC3NEBUPiCtaX7hd4UhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MWSyN|k3PjZ{MR?=
LNCaP MkSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjvTW5HOS1zMECwNEBvVQ>? M{XqXFAuOyCm M1HY[IlvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NX\z[JBCOjN7Nk[2NlE>
C4-2  MoPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnuXmkyNTFyMECwJI5O M3Kw[FAuOyCm NH;uS49qdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NYSwRWlXOjN7Nk[2NlE>
LNCaP MmLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX:xNFAuPTByMDDuUS=> MlvLO|IhcA>? NWLrWmhKcW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kBk\WyuczD1coRmemexaX7nJINmdGxiZHXheIg> MYGyN|k3PjZ{MR?=
C4-2  NGLmOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPK[XFXOTByLUWwNFAhdk1? MkXXO|IhcA>? NGDhZYVqdmO{ZXHz[ZMhfGinIH\yZYN1cW:wIH;mJINmdGy|IIXu[IVz\2:rbnegZ4VtdCCmZXH0bC=> MXWyN|k3PjZ{MR?=
PC-3 NWq2cGV3TnWwY4Tpc44hSXO|YYm= NVnMR48xOC53L{GvNVAh|ryP NGO4OIY1QCCq MYDkc5dvemWpdXzheIV{KHSqZTDwbI9{eGixconsZZRqd25ib3[g[I94dnO2cnXhcUBx[XSqd3H5JJBzd3SnaX7zJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NHS3R4QzOzJ3OEe0NC=>
DU145  NWjw[op5TnWwY4Tpc44hSXO|YYm= MU[wMlUwOS9zMDFOwG0> M3;rN|Q5KGh? M2LUUYRwf26{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBld3ewc4Ty[YFuKHCjdHj3ZZkheHKxdHXpcpMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M1j5NFI{OjV6N{Sw
LNCaP NEntU4xE\WyuIG\pZYJqdGm2eTDBd5NigQ>? NVrFW5N6OC1zMECwJI5O MmLjNE01KGR? MV;y[YR2[2WmIFzOR4FRKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7lduKh NV65bpZXOjN{NUi3OFA>
PC-3  MkfNSpVv[3Srb36gRZN{[Xl? NXSwUVRmOTBizszN MXGxNkBp NVv3TmczcW6mdXPld{BifXSxcHjh[5k> M4PXZVI{OjV6N{Sw

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of AZD5363 (100, 300 mg/kg) to nude mice causes dose- and time-dependent reduction of PRAS40, GSK3β, and S6 phosphorylation in BT474c xenografts, reversible increases in blood glucose concentrations, and dose-dependent decreases in 2[18F]fluoro-2-deoxy-d-glucose (18F-FDG) uptake in U87-MG xenografts. Chronic oral dosing of AZD5363 (130, 200, and 300 mg/kg) causes dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2+ breast cancer models that are resistant to trastuzumab. AZD5363 also significantly enhances the antitumor activity of docetaxel, lapatinib, and trastuzumab in breast cancer xenografts. [2]

Protocol

Kinase Assay:[1]
+ Expand

Caliper Off-Chip Incubation Mobility Shift assay:

The ability of AZD5363 and other compounds to inhibit the activity of AKT1, AKT2, and AKT3 is evaluated by the Caliper Off-Chip Incubation Mobility Shift assay. Active recombinant AKT1, AKT2, or AKT3 are incubated with a 5-FAM-labeled custom-synthesized peptide substrate together with increasing concentrations of inhibitor. Final reactions contained 1 to 3 nM AKT1, AKT2, or AKT3 enzymes; 1.5 mM peptide substrate; ATP at K m for each AKT isoform; 10 mM MgCl2, 4 mM DTT, 100 mM HEPES, and 0.015% Brij-35. The reactions are incubated at room temperature for 1 hour and stopped by the addition of buffer containing 100 mM HEPES, 0.015% Brij-35 solution, 0.1% coating reagent, 40 mM EDTA, and 5% DMSO. Plates are then analyzed using a Caliper LC3000, allowing for separation of peptide substrate and phosphorylated product by electrophoresis with subsequent detection and quantification of laser induced fluorescence.
Cell Research: [2]
+ Expand
  • Cell lines: 182 solid and hematologic tumor cell lines
  • Concentrations: ~30 μM
  • Incubation Time: 72 hours
  • Method: Cell proliferation assay is determined by 2 methods, MTS and Sytox Green. Briefly, cells are seeded in 96-well plates and incubated overnight at 37 ℃, 5% CO2. Cells are then exposed to concentrations of AZD5363 ranging from 30 to 0.003μM for 72 hours. For the MTS endpoint, cell proliferation is measured by the CellTiter AQueous Non-Radioactive Cell Proliferation Assay reagent in accordance with the manufacturer's protocol. For the Sytox Green endpoint, Sytox Green nucleic acid dye diluted in TBS-EDTA buffer is added to cells (final concentration of 0.13 μM) and the number of dead cells detected using an Acumen Explorer. Cells are then permeabilized by the addition of saponin (0.03% final concentration, diluted in TBS-EDTA buffer), incubated overnight and a total cell count measured. Predose measurements are made for both MTS and Sytox Green endpoints, and concentration needed to reduce the growth of treated cells to half that of untreated cells values are determined using absorbance readings (MTS) or live cell counts.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nude mice and male SCID mice with BT474c, U87MG, KPL-4, HCC-1187 xenografts.
  • Formulation: In 10% DMSO 25% w/v Kleptose HPB
  • Dosages: 130 mg/Kg - 300 mg/Kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL (200.5 mM)
Water <1 mg/mL
Ethanol <1 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.92
Formula

C21H25ClN6O2

CAS No. 1143532-39-1
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02576444 Recruiting Cancer Joseph Paul Eder|Dana-Farber Cancer Institute|Vanderbilt-Ingram Cancer Center|Yale University November 2015 Phase 2
NCT02465060 Recruiting Advanced Malignant Neoplasm|Lymphoma|Recurrent Plasma Cell Myeloma|Recurrent Solid Neoplasm|Refractory Malignant Neoplasm|Refractory Plasma Cell Myeloma National Cancer Institute (NCI) August 2015 Phase 2
NCT02664935 Recruiting Non-Small Cell Lung Cancer|Carcinoma, Squamous Cell|Adenocarcinoma University of Birmingham|Cancer Research UK|AstraZeneca|Pfizer|Experimental Cancer Medicine Centre Network March 2015 Phase 2
NCT02451956 Recruiting Advanced Gastric Cancer Samsung Medical Center January 2015 Phase 2
NCT02525068 Recruiting Adenocarcinoma of the Prostate Institute of Cancer Research, United Kingdom|Royal Marsden NHS Foundation Trust December 2014 Phase 2
NCT02208375 Recruiting Breast Cancer|Malignant Female Reproductive System Neoplasm M.D. Anderson Cancer Center|AstraZeneca|National Cancer Institute (NCI) November 2014 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products

Tags: buy AZD5363 | AZD5363 supplier | purchase AZD5363 | AZD5363 cost | AZD5363 manufacturer | order AZD5363 | AZD5363 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID